Physician profile
Michael D Ross
NPI 1679605265
$4,263.17
in general payments reported to CMS, 2019-2025
30 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $414 · 2021: $148 · 2022: $162 · 2023: $957 · 2024: $969 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.65 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $764.91 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $526.41 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $389.78 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $295.35 | 2020-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $234.95 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $182.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.87 | 2022-2025 | |
| Travere Therapeutics, INC. | $167.25 | 2020-2025 | |
| Calliditas Therapeutics US INC. | $151.27 | 2023-2025 | Tarpeyo |
| Genzyme Corporation | $148.33 | 2019 | |
| Novo Nordisk INC | $133.11 | 2024-2025 | Rivfloza, Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $112.86 | 2022-2024 | Lupkynis |
| Vifor Pharma, INC. | $101.23 | 2023-2025 | Veltassa |
| Daiichi Sankyo INC. | $95.62 | 2019-2025 | Injectafer |
| Fresenius USA Marketing, INC. | $91.82 | 2020-2025 | Velphoro, Velphoro, Korsuva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.45 | 2024-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $82.34 | 2023-2025 | Terlivaz, Acthar |
| Glaxosmithkline, LLC. | $81.90 | 2021-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.94 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $72.11 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $63.76 | 2024-2025 | Jardiance |
| Amicus Therapeutics, INC. | $49.50 | 2019-2024 | Galafold |
| Apellis Pharmaceuticals, INC. | $44.84 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $31.42 | 2023 | Givlaari |
| Nxstage Medical, INC. | $26.04 | 2024 | |
| Medtronic, INC. | $23.39 | 2025 | Symplicity G3 |
| Ultragenyx Pharmaceutical INC. | $19.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.08 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.51 | 2019 | |
| Genentech USA, INC. | $14.27 | 2025 | Gazyva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.